CDH13

Aliases:
This biomarker is also known as:
  • CDH13
  • T-cad
  • heart-cadherin
  • truncated-cadherin
  • H-cadherin (heart)
  • H-cadherin
  • T-cadherin
  • P105
  • cadherin 13

Description…

CDH13 is a member of the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region but, unlike the typical cadherin superfamily member, lacks the highly conserved cytoplasmic region. This particular cadherin is a putative mediator of cell-cell interaction in the heart and may act as a negative regulator of neural cell growth. The gene locus is hypermethylated or deleted in breast, ovarian and lung cancers.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Accepted
Type: Genomic
HGNC Name: CDH13

The following organs have data associated with this biomarker…

Attributes

Phase: 3
QA State: Accepted

Overview

Esophageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.

Performance Comment

Levels of CDH13 hypermethylation have been shown to discriminate esophageal adenocarcinoma from esophageal squamous cell carcinoma and normal esophagus. CDH13 is also being investigated as a biomarker for progression from Barrett's esophagus to esophageal adenocarcinoma. Studies are ongoing.

Supporting Study Data

The following studies/protocols provide evidence supporting CDH13 indications for the Esophagus…

Barrett's Esophagus Methylation Profiles

We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.

View more about this study
Biomarker Characteristics Summary

No statistics found.

Decision Rule

PMID:18729198

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Attributes

Phase: 1
QA State: Under Review
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.
Version 5.1.0